ストックスクリーナーアプリを入手
1.50
10.43%
-0.13
アフターアワーズ：
1.35
-0.15
-10.00%
前日終値:
$1.63
開ける：
$1.53
24時間の取引高:
541.97K
Relative Volume:
2.13
時価総額：
$122.25M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-1.2821
EPS:
-1.17
ネットキャッシュフロー:
$-31.63M
1週間 パフォーマンス:
-23.16%
1か月 パフォーマンス:
-29.13%
6か月 パフォーマンス:
-28.08%
1年 パフォーマンス:
+80.25%
1日の値動き範囲:
$1.3201
$1.5849
1週間の範囲:
$1.3201
$1.89
52週間の値動き範囲:
$0.77
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
CNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CNTX | 1.50 | 122.25M | 0 | -30.15M | -31.63M | -1.17 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Context Therapeutics Inc (CNTX) 最新ニュース
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Avidity Partners Management LP Bolsters Stake in Context Therape - GuruFocus.com
Blue Owl Capital Holdings LP Acquires Shares in Context Therapeu - GuruFocus.com
GREAT POINT PARTNERS LLC Adjusts Stake in Context Therapeutics I - GuruFocus.com
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Research Analysts Set Expectations for CNTX FY2024 Earnings - MarketBeat
Circle S.p.A. Advances Digitalization in Logistics - MSN
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results - MarketBeat
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MyChesCo
Redeemer Health Operating Deficit Surpasses $50 Million in Fiscal 2024 - MSN
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
Keiretsu Forum Honors Top Innovators at Investor Capital Expo - MyChesCo
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MyChesCo
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MyChesCo
Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call Transcript - MSN
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Hudson Bay Capital Management LP Acquires Shares in Context Ther - GuruFocus.com
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - The Manila Times
Alto Ingredients, Inc. Reports Third Quarter 2024 Results - The Manila Times
Context Therapeutics Expands Pipeline Despite $17.5M Loss; $84.8M Cash Runway Into 2027 | CNTX Stock News - StockTitan
Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com UK
Protect Your Health: Discover the Life-Saving Potential of Early Lung Cancer Screenings at Local Hospitals - MyChesCo
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MyChesCo
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, - openPR
West Pharmaceutical Services Announces Upcoming Conference Presentations - MyChesCo
Unpacking Q3 Earnings: Herbalife (NYSE:HLF) In The Context Of Other Consumer Staples Stocks - Yahoo Finance
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - StockTitan
Windtree Therapeutics announces $27.24 million equity sale option - Investing.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Intensity Therapeutics grants stock options to top executives - Investing.com
Context Therapeutics Inc (NASDAQ: CNTX) Gains 14.50% In Early Trade; What Lies Ahead? - Stocks Register
Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewswire
Tolerance Bio Secures $17.2 Million to Advance Immune Disease Therapies - MyChesCo
Er +/Her2 -Ve Breast Cancer Pipeline 2024: Clinical Trials - openPR
National Secure Transport Expands Cash Services to Illinois with C3 Industries - MyChesCo
Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MSN
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation - MSN
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan
LVMH shows good resilience in the current context - Yahoo Finance
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):